VirtualScopics, IXICO and Micron in collaboration

RNS Number : 0934H

IXICO plc

11 March 2015

 



VIRTUALSCOPICS, INC. AND IXICO PLC ENTER INTO A COLLABORATION AGREEMENT WITH MICRON, INC.

ROCHESTER, N.Y., LONDON, U.K., AND TOKYO, JAPAN MARCH 11, 2015.  VirtualScopics, Inc. (NASDAQ:VSCP), a leading provider of clinical trial imaging solutions, IXICO plc (AIM:IXI), the brain health company, and Micron, Inc. (Henceforth "Micron", CEO: Makoto Sato, Headquarters: Tokyo, Japan) a provider of imaging services for clinical trials in Asia, jointly announced today that they have entered into a collaboration agreement enhancing each company's global clinical trial imaging solution offerings to Pharma and Biopharma companies.

Erik Jensen, vice president global business development and marketing of VirtualScopics, said "In 2014 we experienced a 25% increase in the number of awarded global Phase III trials over the previous year and we also received new study awards from 9 of the top 15 Pharma companies.  We anticipate our momentum will continue in 2015. The collaboration agreement with Micron, together with our previously signed Alliance Framework Agreement with IXICO, will enable VirtualScopics to continue gaining presence with top Pharma companies and strengthen our global Phase III capabilities in the market place."

John Hall, vice president business development, IXICO, said "we are pleased to be collaborating with Micron.  This expands the Alliance's reach and capabilities internationally and especially in Asia where it offers the opportunity to build on our existing client base in Japan, China and Korea."

Michael Tintiuc, Director of Foreign Affairs, Business Development, Micron, said "This signed collaboration agreement will allow Micron to expand its services outside of Japan to the markets of North America and Europe.  We are excited to work together with VirtualScopics and IXICO and provide our clients a unique opportunity to conduct business from key global locations in the US, UK and Japan."

About VirtualScopics, Inc.

VirtualScopics, Inc. (NASDAQ:VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly-accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, everyday clinical trial imaging services.  For more information on VirtualScopics, Inc. please visit www.virtualscopics.com.

About IXICO plc

IXICO plc, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid decisions and improve patient outcomes.  Established since 2004, IXICO has significant experience in working with global pharmaceutical and biotechnology companies in dementia clinical studies and other neuro-degenerative disorders including Huntington's disease and Multiple Sclerosis.  More information is available on www.ixico.com.

About Micron, Inc.

Micron has established an environment to implement many multicentre imaging clinical trials, especially in Asian countries, such as Japan and Korea. Under this comprehensive collaboration with VirtualScopics and IXICO, we will be able to broaden our services to handle multinational, multicentre clinical trials beyond Asia, including Europe and the U.S and expand our analysis services in the field of oncology and neuroscience.  More information is available on www.micron-kobe.com

Forward-looking Statements

The statements contained in this press release that are not purely historical are forward-looking

statements  within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the company's investment in infrastructure, new office in New Hope, Pennsylvania, the Scientific Advisory Board, the strategic alliance with IXICO, plc, the increase in awards outstanding and bookings and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes", "could", "expects," "anticipates", "estimates", "intends", "plans", "projects," "seeks", or similar expressions.  Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risk of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:

Donna N. Stein, APR, Fellow PRSA

Managing Partner

Donna Stein & Partners

315-361-4672

Email:  [e-mail]

IXICO plc                              

Derek Hill, CEO

John Hall, VP Business Development                        

[phone]

FTI Consulting Limited (IXICO Investor and Public Relations)

Ben Atwell

Simon Conway

Matthew Moss

[phone]

Micron, Inc.

Michael Tintiuc, Director of Foreign Affairs, Business Development

TEL: [phone]

E-mail: [e-mail]

URL  ：http://www.micron-kobe.com/

#          #          #

 

END

 

 

NRAGGURWWUPAGRU